DUKE-NUS, GENSCRIPT AND A*STAR LAUNCH FIRST-IN-THE-WORLD SARS-COV-2 SEROLOGY TEST TO DETECT NEUTRALISING ANTIBODIES WITHOUT NEED OF CONTAINMENT FACILITY OR SPECIMEN
As a first-in-the-world “rapid smart test kit”, the cPassTM; which can measure neutralising antibodies in an hour will be a huge boost to current COVID-19 investigations, from contact tracing, sero-prevalence survey, and assessment of herd immunity, longevity of protective immunity and efficacy of different vaccine candidates.
FROM SINGAPORE TO THE WORLD: WHERE FORTITUDE KIT HAS BEEN DEPLOYED GLOBALLY
Close collaboration between scientists and the public health community have enabled the Fortitude Kit diagnostic to be quickly developed and deployed in Singapore hospitals to detect the SARS-CoV-2 virus that causes COVID-19. From February, Fortitude Kit has been in routine use in 13 Singapore hospitals and labs, public and private. Currently, it is also used by healthcare professionals globally to fight the novel coronavirus pandemic. To date, the kits have been deployed in more than 20 countries globally. See map below for where Fortitude Kit is now in use.
FIGHTING COVID-19 WITH FORTITUDE
The Agency for Science, Technology and Research (A*STAR), and Tan Tock Seng Hospital (TTSH), Singapore, have successfully developed a test kit which can detect the presence of the SARS-CoV-2 virus which causes COVID-19, quickly and with high accuracy.
WOMEN IN SCIENCE: DR RUIFEN WENG, DXD HUB
The 'Women in Science' series aims to break down gender inequalities and celebrates the achievements of our female scientists and researchers in A*STAR. Hear their stories and discover how their unique personal lives and perspectives shape the great work they do.
SINGAPORE TO CATALYSE ASEAN MEDICAL DIAGNOSTICS INITIATIVE AND DEEPEN REGIONAL CONNECTIVITY
Singapore to catalyse ASEAN medical diagnostics initiative and deepen regional connectivity
BIOCARTIS AND A*STAR’S ETPL INITIATE DEVELOPMENT OF BREAST CANCER ASSAY TO GUIDE THERAPY SELECTION
Singapore / Mechelen (Belgium)- 10 July 2017 - Biocartis Group NV (‘Biocartis’ or the ‘Company’)- an innovative molecular diagnostics company (Euronext Brussels: BCART)- today announced that it has extended its partnership with ETPL (the commercialization arm of A*STAR- Singapore’s Agency for Science- Technology and Research1) with a new five-year strategic partnership- focused on the development of molecular diagnostic assays for Biocartis’ Idylla™ platform- a fully automated sample-to-result- real-time PCR (Polymerase Chain Reaction) system that offers accurate- highly reliable molecular information from virtually any biological sample. The first assay selected for development under the partnership is a fully automated solid biopsy assay- aimed at supporting optimal therapy selection decisions for breast cancer patients.
